Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression.

Häyrinen MJ, Uotila PM, Sahi H, Haapasaari KM, Teppo HR, Soini Y, Lapela M, Vasala K, Turpeenniemi-Hujanen T, Ranki A, Kuusisto MEL, Kuittinen O.

J Eur Acad Dermatol Venereol. 2019 Oct 9. doi: 10.1111/jdv.16009. [Epub ahead of print]

PMID:
31596985
2.

Alterations in the expression of EMT-related proteins claudin-1, claudin-4 and claudin-7, E-cadherin, TWIST1 and ZEB1 in oral lichen planus.

Hämäläinen L, Soini Y, Pasonen-Seppänen S, Siponen M.

J Oral Pathol Med. 2019 Sep;48(8):735-744. doi: 10.1111/jop.12917. Epub 2019 Jul 4.

PMID:
31228209
3.

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.

Kari E, Teppo HR, Haapasaari KM, Kuusisto MEL, Lemma A, Karihtala P, Pirinen R, Soini Y, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O.

J Clin Pathol. 2019 Apr;72(4):316-321. doi: 10.1136/jclinpath-2018-205584. Epub 2019 Feb 12.

4.

Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival.

Karihtala P, Porvari K, Soini Y, Eskelinen M, Juvonen P, Haapasaari KM.

Oncology. 2019;96(3):164-170. doi: 10.1159/000494274. Epub 2018 Dec 11.

PMID:
30537722
5.

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.

Peroja P, Pedersen M, Mantere T, Nørgaard P, Peltonen J, Haapasaari KM, Böhm J, Jantunen E, Turpeenniemi-Hujanen T, Rapakko K, Karihtala P, Soini Y, Vasala K, Kuittinen O.

Sci Rep. 2018 Oct 4;8(1):14814. doi: 10.1038/s41598-018-33230-3.

6.

Small oral tongue cancers (≤ 4 cm in diameter) with clinically negative neck: from the 7th to the 8th edition of the American Joint Committee on Cancer.

Almangush A, Mäkitie AA, Mäkinen LK, Kauppila JH, Pukkila M, Hagström J, Laranne J, Soini Y, Kowalski LP, Grénman R, Haglund C, Coletta RD, Salo T, Leivo I.

Virchows Arch. 2018 Oct;473(4):481-487. doi: 10.1007/s00428-018-2417-y. Epub 2018 Jul 23.

PMID:
30039390
7.

Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas.

Valkonen M, Haapasalo H, Rilla K, Tyynelä-Korhonen K, Soini Y, Pasonen-Seppänen S.

BMC Cancer. 2018 Jun 18;18(1):664. doi: 10.1186/s12885-018-4569-1.

8.

Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma.

Isohookana J, Haapasaari KM, Soini Y, Leppänen J, Karihtala P.

Pathol Res Pract. 2018 Jun;214(6):840-847. doi: 10.1016/j.prp.2018.04.016. Epub 2018 May 1.

PMID:
29735403
9.

KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.

Isohookana J, Haapasaari KM, Soini Y, Karihtala P.

Anticancer Res. 2018 Apr;38(4):2295-2302.

PMID:
29599352
10.

R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.

Prusila REI, Haapasaari KM, Marin K, Pollari M, Soini Y, Vornanen M, Karjalainen-Lindsberg ML, Turpeenniemi-Hujanen T, Kuittinen O.

Acta Oncol. 2018 Sep;57(9):1265-1267. doi: 10.1080/0284186X.2018.1450522. Epub 2018 Mar 14. No abstract available.

PMID:
29537344
11.

High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.

Jääskeläinen A, Soini Y, Jukkola-Vuorinen A, Auvinen P, Haapasaari KM, Karihtala P.

BMC Cancer. 2018 Feb 27;18(1):223. doi: 10.1186/s12885-018-4141-z.

12.

NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.

Haapasalo J, Nordfors K, Granberg KJ, Kivioja T, Nykter M, Haapasalo H, Soini Y.

Histol Histopathol. 2018 Aug;33(8):791-801. doi: 10.14670/HH-11-973. Epub 2018 Feb 14.

PMID:
29441509
13.

Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers.

Almangush A, Heikkinen I, Bakhti N, Mäkinen LK, Kauppila JH, Pukkila M, Hagström J, Laranne J, Soini Y, Kowalski LP, Grénman R, Haglund C, Mäkitie AA, Coletta RD, Leivo I, Salo T.

Histopathology. 2018 Jun;72(7):1128-1135. doi: 10.1111/his.13481. Epub 2018 Mar 23.

PMID:
29427291
14.

Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.

Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Soini Y, Karihtala P.

Anticancer Res. 2018 Jan;38(1):329-336.

PMID:
29277791
15.

Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.

Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, Eray M, Jantunen E, Soini Y, Vasala K, Böhm J, Salokorpi N, Koivunen P, Karihtala P, Vuoristo J, Turpeenniemi-Hujanen T, Kuittinen O.

Carcinogenesis. 2017 Aug 1;38(8):812-820. doi: 10.1093/carcin/bgx061.

16.

Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.

Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Soini Y, Karihtala P.

Leuk Lymphoma. 2018 Mar;59(3):679-689. doi: 10.1080/10428194.2017.1344840. Epub 2017 Aug 8.

PMID:
28786706
17.

Evaluation of the budding and depth of invasion (BD) model in oral tongue cancer biopsies.

Almangush A, Leivo I, Siponen M, Sundquist E, Mroueh R, Mäkitie AA, Soini Y, Haglund C, Nieminen P, Salo T.

Virchows Arch. 2018 Feb;472(2):231-236. doi: 10.1007/s00428-017-2212-1. Epub 2017 Aug 2.

PMID:
28766010
18.

Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy.

Teppo HR, Soini Y, Karihtala P.

Oxid Med Cell Longev. 2017;2017:1485283. doi: 10.1155/2017/1485283. Epub 2017 Jun 18. Review.

19.

Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.

Karihtala P, Porvari K, Soini Y, Haapasaari KM.

Oxid Med Cell Longev. 2017;2017:2696071. doi: 10.1155/2017/2696071. Epub 2017 Mar 9.

20.

Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups.

Sundquist E, Kauppila JH, Veijola J, Mroueh R, Lehenkari P, Laitinen S, Risteli J, Soini Y, Kosma VM, Sawazaki-Calone I, Macedo CC, Bloigu R, Coletta RD, Salo T.

Br J Cancer. 2017 Feb 28;116(5):640-648. doi: 10.1038/bjc.2016.455. Epub 2017 Jan 17.

21.

Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma.

Santala S, Talvensaari-Mattila A, Soini Y, Kuvaja P, Santala M.

Anticancer Res. 2016 Dec;36(12):6467-6473.

PMID:
27919969
22.

Epigenetic and genetic changes in soft tissue sarcomas: a review.

Soini Y.

APMIS. 2016 Nov;124(11):925-934. doi: 10.1111/apm.12600. Epub 2016 Sep 27. Review.

PMID:
27670825
23.

Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.

Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Soini Y, Karihtala P.

Anticancer Res. 2016 Sep;36(9):4677-83.

PMID:
27630312
24.

An immunohistochemical study of NFE2L2, KEAP1 and 8-hydroxy-2'-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma.

Hintsala HR, Haapasaari KM, Soini Y, Karihtala P.

Histol Histopathol. 2017 Feb;32(2):129-136. doi: 10.14670/HH-11-778. Epub 2016 May 12.

PMID:
27170270
25.

Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.

Hintsala HR, Jokinen E, Haapasaari KM, Moza M, Ristimäki A, Soini Y, Koivunen J, Karihtala P.

Anticancer Res. 2016 Apr;36(4):1497-506.

PMID:
27069125
26.

Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas.

Törrönen K, Soini Y, Pääkkö P, Parkkinen J, Sironen R, Rilla K.

Histol Histopathol. 2016 Oct;31(10):1113-22. doi: 10.14670/HH-11-740. Epub 2016 Feb 25.

PMID:
26912058
27.

miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS.

Fiore D, Donnarumma E, Roscigno G, Iaboni M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C, Romano G, Greco A, Soini Y, Brunetti A, Croce CM, Condorelli G.

Oncotarget. 2016 Apr 12;7(15):19531-47. doi: 10.18632/oncotarget.6968.

28.

KDM4A, KDM4B and KDM4C in non-small cell lung cancer.

Soini Y, Kosma VM, Pirinen R.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):12922-8. eCollection 2015.

29.

Loss of Peroxiredoxin Expression Is Associated with an Aggressive Phenotype in Pancreatic Adenocarcinoma.

Isohookana J, Haapasaari KM, Soini Y, Karihtala P.

Anticancer Res. 2016 Jan;36(1):427-33.

PMID:
26722077
30.

Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy.

Raatikainen S, Aaaltomaa S, Kärjä V, Soini Y.

Anticancer Res. 2015 Dec;35(12):6465-70.

PMID:
26637857
31.

Twist predicts poor outcome of patients with astrocytic glioma.

Nordfors K, Haapasalo J, Mäkelä K, Granberg KJ, Nykter M, Korja M, Paavonen T, Haapasalo H, Soini Y.

J Clin Pathol. 2015 Nov;68(11):905-12. doi: 10.1136/jclinpath-2015-202868. Epub 2015 Jul 10.

PMID:
26163539
32.

Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.

Mella M, Kauppila JH, Karihtala P, Lehenkari P, Jukkola-Vuorinen A, Soini Y, Auvinen P, Vaarala MH, Ronkainen H, Kauppila S, Haapasaari KM, Vuopala KS, Selander KS.

Oncoimmunology. 2015 May 22;4(6):e1002726. eCollection 2015 Jun.

33.

Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.

Lemma SA, Pasanen AK, Haapasaari KM, Sippola A, Sormunen R, Soini Y, Jantunen E, Koivunen P, Salokorpi N, Bloigu R, Turpeenniemi-Hujanen T, Kuittinen O.

Eur J Haematol. 2016 May;96(5):492-501. doi: 10.1111/ejh.12626. Epub 2015 Aug 7.

PMID:
26153511
34.

Cyclin E Expression Correlates with Cancer-specific Survival in Endometrial Endometrioid Adenocarcinoma.

Santala S, Talvensaari-Mattila A, Soini Y, Santala M.

Anticancer Res. 2015 Jun;35(6):3393-7.

PMID:
26026100
35.

Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.

Pelkonen M, Luostari K, Tengström M, Ahonen H, Berdel B, Kataja V, Soini Y, Kosma VM, Mannermaa A.

BMC Cancer. 2015 May 27;15:431. doi: 10.1186/s12885-015-1440-5.

36.

High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.

Kuusisto ME, Haapasaari KM, Turpeenniemi-Hujanen T, Jantunen E, Soini Y, Peroja P, Bloigu R, Karihtala P, Kuittinen O.

J Clin Pathol. 2015 Jul;68(7):552-6. doi: 10.1136/jclinpath-2014-202771. Epub 2015 May 2.

PMID:
25935550
37.

Keap1 expression has independent prognostic value in pancreatic adenocarcinomas.

Isohookana J, Haapasaari KM, Soini Y, Karihtala P.

Diagn Pathol. 2015 Apr 16;10:28. doi: 10.1186/s13000-015-0258-4.

38.

Vimentin-ERK Signaling Uncouples Slug Gene Regulatory Function.

Virtakoivu R, Mai A, Mattila E, De Franceschi N, Imanishi SY, Corthals G, Kaukonen R, Saari M, Cheng F, Torvaldson E, Kosma VM, Mannermaa A, Muharram G, Gilles C, Eriksson J, Soini Y, Lorens JB, Ivaska J.

Cancer Res. 2015 Jun 1;75(11):2349-62. doi: 10.1158/0008-5472.CAN-14-2842. Epub 2015 Apr 8.

39.

For early-stage oral tongue cancer, depth of invasion and worst pattern of invasion are the strongest pathological predictors for locoregional recurrence and mortality.

Almangush A, Bello IO, Coletta RD, Mäkitie AA, Mäkinen LK, Kauppila JH, Pukkila M, Hagström J, Laranne J, Soini Y, Kosma VM, Koivunen P, Kelner N, Kowalski LP, Grénman R, Leivo I, Läärä E, Salo T.

Virchows Arch. 2015 Jul;467(1):39-46. doi: 10.1007/s00428-015-1758-z. Epub 2015 Apr 3.

PMID:
25838076
40.

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.

Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppä S, Mannisto S, Karjalainen-Lindsberg ML, Lehtinen T, Eray M, Vornanen M, Haapasalo H, Soini Y, Jantunen E, Nousiainen T, Vasala K, Kuittinen O.

Acta Oncol. 2015 Jun;54(6):939-43. doi: 10.3109/0284186X.2014.990110. Epub 2015 Mar 11.

PMID:
25761092
41.

Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors.

Nissi R, Talvensaari-Mattila A, Kuvaja P, Pääkkö P, Soini Y, Santala M.

Anticancer Res. 2015 Feb;35(2):973-6.

PMID:
25667483
42.

Dysregulation of redox-state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment.

Hintsala HR, Soini Y, Haapasaari KM, Karihtala P.

Histopathology. 2015 Sep;67(3):348-57. doi: 10.1111/his.12659. Epub 2015 Mar 8.

PMID:
25627040
43.

KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes.

Hartikainen JM, Tengström M, Winqvist R, Jukkola-Vuorinen A, Pylkäs K, Kosma VM, Soini Y, Mannermaa A.

Clin Cancer Res. 2015 Apr 1;21(7):1591-601. doi: 10.1158/1078-0432.CCR-14-1887. Epub 2015 Jan 14.

44.

A simple novel prognostic model for early stage oral tongue cancer.

Almangush A, Coletta RD, Bello IO, Bitu C, Keski-Säntti H, Mäkinen LK, Kauppila JH, Pukkila M, Hagström J, Laranne J, Tommola S, Soini Y, Kosma VM, Koivunen P, Kowalski LP, Nieminen P, Grénman R, Leivo I, Salo T.

Int J Oral Maxillofac Surg. 2015 Feb;44(2):143-50. doi: 10.1016/j.ijom.2014.10.004. Epub 2014 Nov 11.

PMID:
25457829
45.

SIP1 predicts progression and poor prognosis in pharyngeal squamous cell carcinoma.

Jouppila-Mättö A, Mannermaa A, Sironen R, Kosma VM, Soini Y, Pukkila M.

Histol Histopathol. 2015 May;30(5):569-79. doi: 10.14670/HH-30.569. Epub 2014 Nov 21.

PMID:
25412653
46.

Slug is associated with poor survival in squamous cell carcinoma of the lung.

Merikallio H, T TT, Pääkkö P, Mäkitaro R, Kaarteenaho R, Lehtonen S, Salo S, Salo T, Harju T, Soini Y.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5846-54. eCollection 2014.

47.

Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer.

Tuomarila M, Luostari K, Soini Y, Kataja V, Kosma VM, Mannermaa A.

PLoS One. 2014 Oct 16;9(10):e109508. doi: 10.1371/journal.pone.0109508. eCollection 2014.

48.

Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.

Santala S, Talvensaari-Mattila A, Soini Y, Santala M.

Tumour Biol. 2015 Feb;36(2):953-7. doi: 10.1007/s13277-014-2676-4. Epub 2014 Oct 15.

PMID:
25315186
49.

Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy.

Raatikainen S, Aaltomaa S, Kärjä V, Soini Y.

Hum Pathol. 2014 Nov;45(11):2211-7. doi: 10.1016/j.humpath.2014.07.010. Epub 2014 Jul 31.

PMID:
25175169
50.

miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer.

Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S, Verde P.

Oncogene. 2015 Jun;34(25):3240-50. doi: 10.1038/onc.2014.267. Epub 2014 Aug 25.

Supplemental Content

Support Center